XTALPI Shares Surge Over 4% as First Annual Profit in 2025 Highlights Value of Unique AI Drug Platform

Stock News03-16

XTALPI (02228) rose more than 4% during trading, reaching HK$9.88 per share with a turnover of HK$383 million. The company previously issued a profit alert, projecting revenue of no less than RMB 780 million for 2025, a year-on-year increase of over 193%. Net profit attributable to shareholders is expected to be no less than RMB 100 million, marking the first annual profit after turning a loss into a gain. Analysts noted that the strong 2025 results reflect the accelerating value realization of XTALPI's unique AI-driven drug development platform. In early 2026, the company secured partnerships with multiple industry leaders. It delivered automated and AI robotic laboratory solutions to chemical giant BASF and South Korea’s JW Pharmaceutical. Additionally, RTX-117, the first "AI+RNA" small-molecule innovative drug developed in collaboration with ReviR Therapeutics, completed its first patient dosing and entered clinical development. XTALPI also deepened cooperation with companies such as Dongyang Pharmaceutical, WeSheng Pharma, Yaotang Biotech, and Meda Biotech in specialized areas including endocrine drugs, mRNA therapies, and autoimmune diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184677656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184677656","market":"nz","top_or_hot":-1,"title":"XTALPI Shares Surge Over 4% as First Annual Profit in 2025 Highlights Value of Unique AI Drug Platform","media":"Stock News","content":"<p>XTALPI (02228) rose more than 4% during trading, reaching HK$9.88 per share with a turnover of HK$383 million. The company previously issued a profit alert, projecting revenue of no less than RMB 780 million for 2025, a year-on-year increase of over 193%. Net profit attributable to shareholders is expected to be no less than RMB 100 million, marking the first annual profit after turning a loss into a gain. Analysts noted that the strong 2025 results reflect the accelerating value realization of XTALPI's unique AI-driven drug development platform. In early 2026, the company secured partnerships with multiple industry leaders. It delivered automated and AI robotic laboratory solutions to chemical giant BASF and South Korea’s JW Pharmaceutical. Additionally, RTX-117, the first \"AI+RNA\" small-molecule innovative drug developed in collaboration with ReviR Therapeutics, completed its first patient dosing and entered clinical development. XTALPI also deepened cooperation with companies such as Dongyang Pharmaceutical, WeSheng Pharma, Yaotang Biotech, and Meda Biotech in specialized areas including endocrine drugs, mRNA therapies, and autoimmune diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XTALPI Shares Surge Over 4% as First Annual Profit in 2025 Highlights Value of Unique AI Drug Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXTALPI Shares Surge Over 4% as First Annual Profit in 2025 Highlights Value of Unique AI Drug Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 14:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XTALPI (02228) rose more than 4% during trading, reaching HK$9.88 per share with a turnover of HK$383 million. The company previously issued a profit alert, projecting revenue of no less than RMB 780 million for 2025, a year-on-year increase of over 193%. Net profit attributable to shareholders is expected to be no less than RMB 100 million, marking the first annual profit after turning a loss into a gain. Analysts noted that the strong 2025 results reflect the accelerating value realization of XTALPI's unique AI-driven drug development platform. In early 2026, the company secured partnerships with multiple industry leaders. It delivered automated and AI robotic laboratory solutions to chemical giant BASF and South Korea’s JW Pharmaceutical. Additionally, RTX-117, the first \"AI+RNA\" small-molecule innovative drug developed in collaboration with ReviR Therapeutics, completed its first patient dosing and entered clinical development. XTALPI also deepened cooperation with companies such as Dongyang Pharmaceutical, WeSheng Pharma, Yaotang Biotech, and Meda Biotech in specialized areas including endocrine drugs, mRNA therapies, and autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1184677656","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184677656","pubTimestamp":1773642623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XTALPI (02228) rose more than 4% during trading, reaching HK$9.88 per share with a turnover of HK$383 million. The company previously issued a profit alert, projecting revenue of no less than RMB 780...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","01477":"欧康维视生物-B","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","BK1141":"生命科学工具和服务","02228":"晶泰控股","BK1617":"AI医疗"},"translate_title":"XTALPI股价飙升超过4%，2025年首次实现年度利润凸显独特人工智能药物平台的价值","themeId":"3923f54d12d0c12982608f5f8a99e8da","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"VXUS":1,"02228":1},"content_text":"XTALPI (02228) rose more than 4% during trading, reaching HK$9.88 per share with a turnover of HK$383 million. The company previously issued a profit alert, projecting revenue of no less than RMB 780 million for 2025, a year-on-year increase of over 193%. Net profit attributable to shareholders is expected to be no less than RMB 100 million, marking the first annual profit after turning a loss into a gain. Analysts noted that the strong 2025 results reflect the accelerating value realization of XTALPI's unique AI-driven drug development platform. In early 2026, the company secured partnerships with multiple industry leaders. It delivered automated and AI robotic laboratory solutions to chemical giant BASF and South Korea’s JW Pharmaceutical. Additionally, RTX-117, the first \"AI+RNA\" small-molecule innovative drug developed in collaboration with ReviR Therapeutics, completed its first patient dosing and entered clinical development. XTALPI also deepened cooperation with companies such as Dongyang Pharmaceutical, WeSheng Pharma, Yaotang Biotech, and Meda Biotech in specialized areas including endocrine drugs, mRNA therapies, and autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184677656","isCrawlerRequest":true}